Uncategorized

MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset

by Business Wire • 2022/11/08 • 0 Comments

SAN DIEGO--(BUSINESS WIRE)--MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset